Citations

Clear

912 citation(s) found for "Yu, Caroline".

Increasing adipose burden in young men with metastatic testicular cancer following front-line cytotoxic chemotherapy.
Kato, Caroline, Batra, Kunnal, Mullane, Michael Russell, Lad, Thomas E. , Master, Viraj A. , Arora, Karan , Psutka, Sarah P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 525-525

10.1200/jco.2019.37.7_suppl.525 Get It

525 Background: Exposure to cytotoxic chemotherapy (CC) has been observed to be associated with significant changes in body composition, namely marked lean muscle mass losses, with implications for treatment-related toxicity and oncologic outcomes. However, prior studies predominately include elderly patients who, a priori, are at risk for sarcopenia or severe skeletal muscle deficiency. To date, the impact of CC on body composition in young men with testicular cancer remains undefined. Methods: A retrospective analysis of 19 patients with metastatic testicular cancer treated with CC was performed (2015-17). Lumbar skeletal muscle index (SMI), visceral (VAI), subcutaneous (SCAI), and intramuscular adipose (IMAI) indices (cm2/m2), as well as fat-free mass (FFM, kg) and fat mass (FM, kg) were calculated using cross-sectional soft tissue area measurements on pre- and post-CC computed tomography (CT) axial scans and compared using paired Wilcoxon Signed Rank Tests. Results: Median age was 29 years. According to the NHANES FMI-based classification, 5 (26.3%), 9 (47.4%), 4 (21.1%), and 1 (5.3%) patients had normal, excess, class I, and class II obesity, respectively. Median pre- and post-CC BMI was 27.7 vs. 29.6 kg/m2(p = 0.03). Median pre- and post-CC SMI, VAI, SAI, and IAI were 63.5 vs 57.8 (p = 0.14), 19.9 vs 30.8 (p = 0.01), 47.9 vs 58.2 (p = 0.03), and 3.0 vs 5.2 (p = 0.002), respectively. Median muscle density pre- and post-CC were 47.0 vs 43.6 HU (p = 0.002). Pre- and post-chemotherapy FFM were 21.5 vs 19.5 kg, representing an overall median loss of 2.8%, (IQR -10.1, +4.7; Range -49.5 - +16.3; p = 0.14). Conversely, pre- and post-CC FM were 6.6 vs 7.5 kg, representing an overall median gain of 13.3% (IQR -3.3, +17.0; -24.9 - +50; p = 0.01). Median time between imaging assessments was 121 days. Specific median measures of adiposity each increased significantly, such that VIA increased by 29% (p = 0.01), SCAI increased by 39.7% (p = 0.03), and IMIA increased by 39.7% (p = 0.002). Conclusions: While lean muscularity remained stable, we observed significant increases in total body adipose mass with decreased muscle density in this consecutive case series of testicular cancer patients following CC.
Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.
Gangadhar, Tara C., Hamid, Omid , Dummer, Reinhard , Mehnert, Janice M. , Celentano, Kellie Ann, Lindia, Jill A., Chatterjee, Manash , Turner, David C. , Mayawala, Kapil , Elassaiss‐Schaap, Jeroen , Alwis, Dinesh P. de, Li, Xiaoyun , Ebbinghaus, Scot, Kang, Soonmo Peter, Kefford, Richard , Joseph, Richard W. , Puzanov, Igor , Robert, Caroline , Ribas, Antoni , Daud, Adil

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3068-3068

10.1200/jco.2015.33.15_suppl.3068 Get It

Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.
Hamid, Omid , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Li, Xiaoyun , Xue, Dahai, Ebbinghaus, Scot, Kang, Soonmo Peter, Perrone, Andrea , Hodi, F. Stephen , Wolchok, Jedd D. , Ribas, Antoni , Robert, Caroline , Weber, Jeffrey S. , Joshua, Anthony M. , Daud, Adil , Joseph, Richard W. , Perrone, Andrea Marie

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3000-3000

10.1200/jco.2015.33.15_suppl.3000 Get It

NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.
Brown, Paul D. , Asher, Anthony L. , Farace, Elana, Cerhan, Jane H. , Anderson, S. Keith , Carrero, Xiomara W., Barker, Frederick G., Deming, Richard L., Burri, Stuart H., Ménard, Cynthia , Pollock, Bruce E. , Buckner, Jan C. , Jaeckle, Kurt A. , Ballman, Karla V. , Chung, Caroline , Stieber, Volker W. , Galanis, Evanthia

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2015.33.15_suppl.lba4 Get It

Home Blenderized Tube Feeding: A Practical Guide for Clinical Practice
Weeks, C. R. , Weeks, Caroline

Mayo Clinic

Clinical and Translational Gastroenterology | March 1, 2019 | Volume: 10 | Issue: 2 | Pages: e00001

10.14309/ctg.0000000000000001 | PMID 30730397 Get It

Although commercial enteral formulas have been available on the market for several decades, a cultural shift toward consuming unprocessed foods with minimally added sugar has sparked interest in the preparation of home blenderized tube feedings for enteral feeding-dependent patients. Recent surveys, however, indicate lack of clinical awareness or familiarity in the management of this method of nutrition support. This article aims to equip the gastroenterologist with a guide for initiation, monitoring, and evaluation of a blenderized tube feedings regimen, and provides insights into an opportunity for greater partnership between the gastrointestinal provider and registered dietitian.
International Triadin Knockout Syndrome Registry
Clemens, Daniel J. , Tester, David J. , Giudicessi, John R. , Bos, J. Martijn , Rohatgi, Ram K., Abrams, Dominic J. , Balaji, Seshadri , Crotti, Lia , Fauré, Julien , Napolitano, Carlo , Priori, Silvia G. , Rooryck, Caroline , Roux-Buisson, Nathalie , Sacher, Frédéric , Silka, Michael J. , Walsh, Mark, Ackerman, Michael J. , Crotti, Lia , Bos, Johan M , Abrams, Dominic J , Probst, Vincent , Schwartz, Peter J. , Priori, Silvia , Rooryck, Caroline

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 19, 2019 | Volume: 12 | Issue: 2 | Pages: No page available

10.1161/circgen.118.002419 | PMID 30649896 Get It

Background: Triadin knockout syndrome (TKOS) is a rare, inherited arrhythmia syndrome caused by recessive null mutations in TRDN -encoded cardiac triadin. Based previously on 5 triadin null patients, TKOS has been characterized by extensive T-wave inversions, transient QT prolongation, and severe disease expression of exercise-induced cardiac arrest in early childhood refractory to conventional therapy. Methods: We have established the International Triadin Knockout Syndrome Registry to include patients who have genetically proven homozygous/compound heterozygous TRDN null mutations. Clinical/genetic data were collected using an online survey generated through REDCap. Results: Currently, the International Triadin Knockout Syndrome Registry includes 21 patients (11 males, average age of 18 years) from 16 families. Twenty patients (95%) presented with either cardiac arrest (15, 71%) or syncope (5, 24%) at an average age of 3 years. Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29%) patients. Of the 19 surviving patients, 16 (84%) exhibit T-wave inversions, and 10 (53%) have transient QT prolongation > 480 ms. Eight of 9 patients had ventricular ectopy on exercise stress testing. Thirteen (68%) patients have received implantable defibrillators. Despite various treatment strategies, 14 (74%) patients have had recurrent breakthrough cardiac events. Conclusion: TKOS is a potentially lethal disease characterized by T-wave inversions in the precordial leads, transient QT prolongation in some, and recurrent ventricular arrhythmias at a young age despite aggressive treatment. Patients displaying this phenotype should undergo TRDN genetic testing as TKOS may be a cause for otherwise unexplained cardiac arrest in young children. As gene therapy advances, enrollment into the International Triadin Knockout Syndrome Registry is encouraged to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.
Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study
Mutsaerts, Henk , Mirza, Saira Saeed , Petr, Jan , Thomas, David L. , Cash, David M. , Bocchetta, Martina , Metcalfe, Arron W.S. , Shirzadi, Zahra , Robertson, Andrew D. , Tartaglia, Maria Carmela , Mitchell, Sara, Freedman, Morris , Tang‐Wai, David F. , Keren, Ron , Laforce, Robert , Tagliavini, Fabrizio , Borroni, Barbara , Galimberti, Daniela , Rowe, James B. , Graff, Caroline , Frisoni, Giovanni B. , Finger, Elizabeth , Sorbi, Sandro , Mendonça, Alexandre de , Rohrer, Jonathan D. , MacIntosh, Bradley J. , (GENFI), GENetic Frontotemporal dementia Initiative, Andersson, Christin, Archetti, Silvana, Arighi, Andrea , Benussi, Luisa , Binetti, Giuliano, Cosseddu, Maura , Dick, Katrina M., Fallström, Marie, Fenoglio, Chiara , Fumagalli, Giorgio, Gazzina, Stefano , Ghidoni, Roberta , Grisoli, Marina , Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Mead, Simon , Meeter, Lieke , Minkelen, Rick van , Öijerstedt, Linn , Ourselin, Sébastien , Padovani, Alessandro , Panman, Jessica , Pievani, Michela, Polito, Cristina , Premi, Enrico, Prioni, Sara, Rademakers, Rosa, Redaelli, Veronica, Rossi, Giacomina , Thonberg, Håkan, Tiraboschi, Pietro , Verdelho, Ana, Warren, Jason D. , Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Binetti, Giuliano , Redaelli, Veronica , Prioni, Sara , Fumagalli, Giorgio , Frisoni, Giovanni B. , Finger, Elizabeth C. , Rowe, James B , Rohrer, Jonathan D , Padovani, Alessandro , Tartaglia, Maria Carmela , Cash, David M , Vita, Enrico De , Black, Sandra E. , Rogaeva, Ekaterina A. , Swieten, John C. van , Masellis, Mario , (GENFI), GENetic Frontotemporal dementia Initiative, Binetti, Giuliano, Fallström, Marie, Ferreira, Carlos , Fox, Nick C. , Fumagalli, Giorgio, Jelic, Vesna, Jiskoot, Lize C. , Lombardi, Gemma, Maruta, Carolina, Nacmias, Benedetta , Pievani, Michela, Premi, Enrico, Prioni, Sara, Rademakers, Rosa , Redaelli, Veronica, Rossor, Martin N. , Scarpini, Elio , Verdelho, Ana, Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Galimberti, Daniela , de Mendonça, Alexandre , Bocchetta, Martina , Tiraboschi, Pietro , Laforce, Robert , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | February 2, 2019 | Volume: 142 | Issue: 4 | Pages: 1108-1120

10.1093/brain/awz039 | PMID 30847466 Get It

Abstract Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with presymptomatic carriers from families representing those at risk. While cerebral blood flow shows differences between frontotemporal dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal dementia. This study aimed to delineate the cerebral blood flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated cross-sectional differences in arterial spin labelling MRI-based cerebral blood flow between presymptomatic C9orf72, GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses. Cerebral blood flow within regions of interest derived from this model was then explored to identify differences between individual gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a significant inverse association between cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers. Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup. These cerebral blood flow differences first appeared approximately 12.5 years before the expected symptom onset determined on an individual basis. Cerebral blood flow was lower in presymptomatic mutation carriers closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms
Goyal, Gaurav , Lau, Denise , Nagle, Alison M., Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Tobin, W. Oliver , Liu, Minetta C. , Tobin, W Oliver , Goyal, Guarav , Vassallo, Robert , Ryu, Jay H , Rech, Karen L. , Koster, Matthew J. , Bennani, N. Nora , Shah, Meera , Go, Ronald S.

Mayo Clinic

Blood | January 29, 2019 | Volume: 133 | Issue: 14 | Pages: 1607-1610

10.1182/blood-2018-12-893917 | PMID 30696619 Get It

P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
Dulai, Parambir S. , Amiot, Aurélien , Singh, Siddharth , Serrero, Mélanie , Jairath, Vipul , Filippi, Jérôme, Kane, Sunanda V. , Bouhnik, Yoram , Sandborn, William J. , Lasch, Karen, Rosario, Maria , Feagan, Brian G. , Bojic, Daniela, Trang-Poisson, Caroline, Shen, Bo , Altwegg, Romain , Sands, B E, Colombel, J F, Carbonnel, Franck , Bohm, Matthew , Bourrier, Anne, Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Peyrin‐Biroulet, Laurent , Pariente, Benjamin , Loftus, Edward V. , Roblin, Xavier , Buisson, Anthony , Siegel, Corey A , Trang, Caroline , Hudesman, David , Lukin, Dana J.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S316-S316

10.1093/ecco-jcc/jjy222.537 Get It